Cargando…
A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19
Autores principales: | Wagener, Gebhard, Goldklang, Monica P., Gerber, Adam, Elisman, Katerina, Eiseman, Katherine A., Fonseca, Laura D., D’Armiento, Jeanine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332096/ https://www.ncbi.nlm.nih.gov/pubmed/35902867 http://dx.doi.org/10.1186/s13054-022-04096-9 |
Ejemplares similares
-
Telemedicine for Patients with Chronic Pulmonary Diseases in the COVID-19 Era and Beyond
por: Goldklang, Monica, et al.
Publicado: (2022) -
Second hand smoke and COPD: lessons from animal studies
por: Goldklang, Monica P., et al.
Publicado: (2013) -
Renal neoplasms in tuberous sclerosis mice are neurocristopathies
por: Unachukwu, Uchenna, et al.
Publicado: (2021) -
Suppression of cigarette smoke induced MMP1 expression by selective serotonin re‐uptake inhibitors
por: Adam, Gerber, et al.
Publicado: (2021) -
Multimodality molecular imaging of the alveolar-capillary barrier in lung disease using albumin based optical and PET tracers
por: Molotkov, Andrei, et al.
Publicado: (2020)